Pharmaceuticals, Biotechnology and Life Sciences
Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full…
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond…
U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908…
Findings unveiled at the University of Florida Scientific Kratom Symposium highlight encouraging results for adult use of low-dose proprietary kratom…
Integrated analysis of systemic inflammation and tumor immune features identifies biologically distinct patient subgroups with differential survival outcomes, outperforming conventional…
Single-dose designed peptide drives structural and functional cardiac repair in a mouse myocardial infarction model SAN FRANCISCO–(BUSINESS WIRE)–Animate Biosciences, a…
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an…
CyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy…
MALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, today…
ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries Dublin-based subsidiary to…